Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edward Paule who wrote (11257)	8/16/1999 10:45:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Ed, I never said there was a legal document. The FDA does not I REPEAT does NOT like companies grandstanding their data when up for possible approval. Xoma feels that releasing data at this time is a very stupid move. When I don't want to make a stupid move sometimes I just might tell you I can't or won't make that move. NO LEGAL DOCUMENT REQUIRED.<g> If you disagree with that, so be it.

To: Edward Paule who wrote (11257)	8/16/1999 11:01:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Ed, your post made me think you were trying to prove there could be no bad news since XOMA which already has experienced a lawsuit knows that it must release bad news, and of course that it must not hype. XOMA did not tell shareholders the drug failed. They said they believed it was clinically effective. "<<<<<<<< If Xoma "knows" now and doesn't "tell" until October, and Xoma tanks as a result, then everyone who buys between tomorrow and October could very well be members of a class action lawsuit.>>>>>>>>" wammy. Obvious that XOMA does not know its' drug is not effective. Nor can those that sell now thinking it was not effective prevail in any subsequent lawsuit. XOMA will be able to prove it said that it believed the drug was effective. <g> No there is nothing or no page that says nothing can be said until the FDA lets one say it. But given the nature of the approval process it is probably wiser to avoid automatic law suits which could follow when a regulatory agency does something perverse. One avoids a double whammy. So, even though I would like to have hard data and think they should release the number of deaths in each arm I can see why a conservative management would not.